At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03378 HANXBIO-B
Not Yet Opened 07-27 16:08:02
26.100
-0.800
-2.97%
High28.740Low25.500Vol67.40K
Open26.840D1 Closing26.900Amplitude12.04%
Mkt Cap3.50BTradable Cap3.50BTotal Shares134.00M
T/O1.77MT/O Rate0.05%Tradable Shares134.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hanx Biopharma Files HKEX Next-day Disclosure Return on Share Repurchase
Reuters  ·  07-15
Hanx Biopharma Files HKEX Next-day Disclosure Return on Share Repurchase
Hanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units
Bulletin Express  ·  07-14
Hanx Biopharmaceuticals repurchases 58,200 H-shares, lifts treasury stock to 2.03 million units
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure After Share Repurchase
Reuters  ·  07-14
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure After Share Repurchase
HANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%
Bulletin Express  ·  07-13
HANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure Return on Share Repurchase
Reuters  ·  07-13
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure Return on Share Repurchase
Hanx Biopharma Files HKEX Next-day Return Disclosing Share Buyback at HKD 28.96 Each
Reuters  ·  07-10
Hanx Biopharma Files HKEX Next-day Return Disclosing Share Buyback at HKD 28.96 Each
HANXBIO-B spends HK$1.04 million to repurchase 36,400 H-shares, treasury stock rises to 1.88 million shares
Bulletin Express  ·  07-09
HANXBIO-B spends HK$1.04 million to repurchase 36,400 H-shares, treasury stock rises to 1.88 million shares
Hanx Biopharmaceuticals Files HKEX Next-day Return Disclosing Share Buyback at HKD 28.63 Each
Reuters  ·  07-09
Hanx Biopharmaceuticals Files HKEX Next-day Return Disclosing Share Buyback at HKD 28.63 Each
HANXBIO-B Executes Share Buyback, Spending HK$980,100
Stock News  ·  07-08
HANXBIO-B Executes Share Buyback, Spending HK$980,100
HANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million
Bulletin Express  ·  07-08
HANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million
HANXBIO-B (03378) Repurchases 21,000 Shares for HK$607,000 on July 7
Stock News  ·  07-07
HANXBIO-B (03378) Repurchases 21,000 Shares for HK$607,000 on July 7
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure Return on Share Repurchase at HKD 28.91 Avg Price
Reuters  ·  07-07
Hanx Biopharmaceuticals Files HKEX Next-day Disclosure Return on Share Repurchase at HKD 28.91 Avg Price
HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework
Stock News  ·  07-07
HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework
Hanx Biopharmaceuticals partners with HUST Advanced Interdisciplinary Research Centre to establish AI-driven drug-discovery lab
Bulletin Express  ·  07-07
Hanx Biopharmaceuticals partners with HUST Advanced Interdisciplinary Research Centre to establish AI-driven drug-discovery lab
Hanx Biopharmaceuticals Posts Announcement on Ai-driven Drug Discovery Collaboration
Reuters  ·  07-07
Hanx Biopharmaceuticals Posts Announcement on Ai-driven Drug Discovery Collaboration
Hanx Biopharmaceuticals (wuhan) Co - Enters Agreement to Establish Joint Ai-driven Drug Discovery Lab
THOMSON REUTERS  ·  07-07
Hanx Biopharmaceuticals (wuhan) Co - Enters Agreement to Establish Joint Ai-driven Drug Discovery Lab
Hanx Biopharmaceuticals (wuhan) Co - Collaborates with Hust-cityu Macau Institute Advanced Interdisciplinary Research Centre
THOMSON REUTERS  ·  07-07
Hanx Biopharmaceuticals (wuhan) Co - Collaborates with Hust-cityu Macau Institute Advanced Interdisciplinary Research Centre
HANXBIO-B Repurchases 29,500 Shares for HK$854,500
Stock News  ·  07-06
HANXBIO-B Repurchases 29,500 Shares for HK$854,500
HANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares
Bulletin Express  ·  07-06
HANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares
HANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares
Bulletin Express  ·  07-03
HANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares

Introduction

Company Name.
HANXBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.
Issue price:
--